Pfizer Inc. (BVL:PFEUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 558.37B +11.0% |
| Revenue (ttm) | 217.17B -0.2% |
| Net Income | 14.78B -59.7% |
| EPS | 2.59 -59.9% |
| Shares Out | n/a |
| PE Ratio | 37.67 |
| Forward PE | 9.93 |
| Dividend | 6.01 (6.36%) |
| Ex-Dividend Date | Nov 6, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 27.41 |
| Day's Range | n/a |
| 52-Week Range | 23.72 - 28.72 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Pfizer price target raised to $30 from $28 at JPMorgan
JPMorgan raised the firm’s price target on Pfizer (PFE) to $30 from $28 and keeps a Neutral rating on the shares.
Pfizer price target raised to $29 from $27 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Pfizer (PFE) to $29 from $27 and keeps a Neutral rating on the shares as part of the firm’s Q3…
Pfizer price target raised to $28 from $27 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Pfizer (PFE) to $28 from $27 and keeps a Neutral rating on the shares. MEVPRO-1 has largely defined the near-term setup, leaving…
Pfizer to cut 300 jobs in Italy, confirms closure of penicillins department
In a statement, CISL, a national trade union in Italy, said, “The meeting held yesterday afternoon at the Ministry of Enterprise and Made in Italy on the dispute at the…
Pfizer announces FDA approval of TUKYSA regimen for HER2+ breast cancer
Pfizer (PFE) announced that the U.S. Food and Drug Administration has approved TUKYSA in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally a...
Pfizer's TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for ...
Pfizer to cut around 330 jobs in Italy
Pfizer will cut around 330 jobs in Italy at its Sicily plant, labour unions said on Wednesday, making the US drugmaker the latest international company downsizing its Italian operations.
Pfizer price target raised to $33 from $30 at Scotiabank
Scotiabank raised the firm’s price target on Pfizer (PFE) to $33 from $30 and keeps an Outperform rating on the shares. The firm believes the increase is warranted due to…
Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer – – VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gast...
Pfizer price target raised to $33 from $30 at Scotiabank
Scotiabank raised the firm’s price target on Pfizer (PFE) to $33 from $30 and keeps an Outperform rating on the shares.
Pfizer Declares Fourth-Quarter 2026 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company's common stock, payable December 7, 2026, to...
Pfizer says LITFULO significantly improved repigmentation in patients
Pfizer (PFE) presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO as a once-daily oral treatment across a wide range of disease extent. In the…
Pfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a...
Trump Medicare drug pricing model may apply to only four companies after exemptions
A Trump administration rule to cut hospital drug prices for Medicare patients may apply to as few as four drugmakers after exempting companies that signed separate "most favored nation" pricing agre...
Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims
Florida Attorney General James Uthmeier on Thursday filed a lawsuit against Pfizer and its CEO, Albert Bourla, accusing the drugmaker of misleading consumers about the safety and effectiveness of it...
Florida sues Pfizer over COVID vaccine marketing
Florida Attorney General James Uthmeier filed a lawsuit against Pfizer (PFE) and its CEO Dr. Albert Bourla. Uthmeier said via X: “Weeks ago we learned Fauci and the biomedical state…
Pfizer says Phase 2 study of tilrekimig met primary endpoint
Pfizer (PFE) presented detailed results from an ongoing Phase 2 study investigating tilrekimig in adults with moderate-to-severe atopic dermatitis. The study met its primary endpoint, demonstrating a ...
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermat...
Nurix Therapeutics announces achievement of $7M milestone with Pfizer
Nurix Therapeutics (NRIX) announced the achievement of a $7M research milestone under its strategic collaboration with Pfizer (PFE) for the discovery and development of degrader antibody conjugates. N...
Pfizer Advances Today's Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncolog...
Pfizer CEO Bourla plans to attend White House state dinner, Reuters reports
Pfizer (PFE) CEO Albert Bourla is expected to attend President Trump’s September 24 state dinner for Chinese President Xi Jinping, as the leaders seek greater stability in U.S.-China relations amid…
Pfizer CEO Bourla plans to attend White House state dinner for China's Xi, source says
Pfizer CEO Albert Bourla plans to attend U.S. President Donald Trump's state dinner for Chinese President Xi Jinping on Thursday evening, according to a source familiar with the matter on Tuesday.
Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, ...
Pfizer Transcript: U.S. All Stars Conference
Resource reallocation and commercial focus have driven strong growth in new products and improved efficiency, while a maturing pipeline and targeted portfolio management support future expansion. AI and digital tools are enhancing productivity, and the company is well-positioned in obesity and oncology markets.